A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer

Tanya Dorff,Lisa G. Horvath,Karen Autio,Alice Bernard-Tessier,Matthew B. Rettig,Jean-Pascal Machiels,Mehmet A. Bilen,Martijn P. Lolkema,Nabil Adra,Sylvie Rottey,Richard Greil,Nobuaki Matsubara,Daniel S.W. Tan,Alvin Wong,Hiroji Uemura,Charlotte Lemech,Johannes Meran,Youfei Yu,Mukul Minocha,Mason McComb,Hweixian Leong. Penny,Vinita Gupta,Xuguang Hu,Gabor Jurida,Hosein Kouros-Mehr,Margit M. Janát-Amsbury,Tobias Eggert,Ben Tran
DOI: https://doi.org/10.1158/1078-0432.ccr-23-2978
IF: 13.801
2024-02-02
Clinical Cancer Research
Abstract:Purpose: Safety and efficacy of acapatamab, a prostate-specific membrane antigen (PSMA) x CD3 bispecific T-cell engager were evaluated in a first-in-human study in metastatic castration-resistant prostate cancer (mCRPC). Patients and Methods: Patients with mCRPC refractory to androgen receptor pathway inhibitor therapy and taxane-based chemotherapy received target acapatamab doses ranging from 0.003 mg–0.9 mg in dose exploration (7 dose levels) and 0.3 mg (recommended phase 2 dose) in dose expansion intravenously Q2W. Safety (primary objective), pharmacokinetics, and antitumor activity (secondary objectives) were assessed. Results: In all, 133 patients (dose exploration, n=77; dose expansion, n=56) received acapatamab. Cytokine release syndrome (CRS) was the most common treatment-emergent adverse event seen in 97.4% and 98.2% of patients in dose exploration and dose expansion respectively; grade ≥ 3 was seen in 23.4% and 16.1%, respectively. Most CRS events were seen in treatment cycle 1; incidence and severity decreased at/beyond cycle 2. In dose expansion, confirmed prostate-specific antigen responses (PSA50) were seen in 30.4% of patients and radiographic partial responses in 7.4% (RECIST 1.1). Median PSA progression-free survival (PFS) was 3.3 months (95% CI, 3.0–4.9), radiographic PFS per PCWG3 was 3.7 months (95% CI, 2.0–5.4). Acapatamab induced T-cell activation and increased cytokine production several-fold within 24h of initiation. Treatment-emergent antidrug antibodies were detected in 55% and impacted serum exposures in 36% of patients in dose expansion. Conclusions: Acapatamab was safe and tolerated and had a manageable CRS profile. Preliminary signs of efficacy with limited durable antitumor activity were observed. Acapatamab demonstrated pharmacokinetic and pharmacodynamic activity.
oncology
What problem does this paper attempt to address?